ClinicalTrials.gg
CompletedNCT05976386Updated Sep 19, 2025

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

A Phase 1 interventional study of Dupilumab (SAR231893) in Healthy Volunteers, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.
  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2021, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a parallel group, treatment, Phase 1, open-label, 2-arm study to demonstrate pharmacokinetic comparability between subcutaneous (SC) single dose of new dupilumab product and SC single dose of current dupilumab product in male and female healthy participants aged 18 to 65 years.

The estimated duration is up to 21 days of screening period, followed by the treatment day with a follow-up treatment period of 42 days until the end of study (EOS) visit. Total duration from screening to EOS will be 64 days maximum.

Read the detailed description

Duration per participant is up to 64 days

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, between 18 and 65 years of age, inclusive.
  • Body weight between 65.0 and 95.0 kg, inclusive.
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Having given written prior to undertaking any study-related procedure.

Exclusion criteria

Exclusion Criteria:

  • Presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation, any volume, within 2 months before inclusion.
  • Presence or history of drug or biologic , or allergic disease diagnosed and treated by a physician (excluding seasonal allergy).
  • History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis).
  • Smoking regularly and unable to stop smoking during the inpatient portion of the study (occasional smoker can be enrolled).
  • If female, pregnancy (defined as positive β-human chorionic gonadotropin (HCG) blood test) or breastfeeding.
  • Any biologics (antibody or its derivatives) given within 4 months before inclusion or within 5 half-lives (whichever takes longer).
  • Participation in any previous clinical trial of dupilumab.
  • Participation in any clinical research study evaluating another drug or therapy in which the inclusion visit for the current study will be within 30 days of receiving the drug or 5 elimination half-lives (whichever is longer).
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    New dupilumab product

    A single subcutaneous injection on Day 1

    Drug: Dupilumab (SAR231893)

  • Active comparator
    Current dupilumab product

    A single subcutaneous injection on Day 1

    Drug: Dupilumab (SAR231893)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum serum concentration of functional dupilumab (Cmax)

    Time frame: Pre-dose on Day 1 up to Day 43

  2. Area under the serum concentration versus time curve from time zero to the real time of last measurable concentration (AUClast)

    Time frame: Pre-dose on Day 1 up to Day 43

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Day 1 up to Day 43

07

Study locations

1 site
  • Clinical Pharmacology of Miami-Site Number:8400001
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartActual
Jun 8, 2021
Primary completionActual
Sep 24, 2021
CompletionActual
Sep 24, 2021
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05976386
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Jun 8, 2021
Primary completion
Sep 24, 2021
Completion
Sep 24, 2021
Last update
Sep 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion